JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

MacroGenics Inc

Cerrado

SectorSanidad

1.84 0.55

Resumen

Variación precio

24h

Actual

Mínimo

1.81

Máximo

1.87

Métricas clave

By Trading Economics

Ingresos

4.8M

-36M

Ventas

9M

22M

Margen de beneficios

-162.992

Empleados

341

EBITDA

5.7M

-33M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+104.92% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

15M

108M

Apertura anterior

1.29

Cierre anterior

1.84

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

145 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

MacroGenics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 oct 2025, 18:41 UTC

Ganancias

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct 2025, 18:31 UTC

Ganancias

Correction to Procter & Gamble to Focus on Innovation

24 oct 2025, 16:25 UTC

Principales Movimientos del Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct 2025, 21:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 oct 2025, 21:24 UTC

Charlas de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct 2025, 21:07 UTC

Ganancias

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct 2025, 20:58 UTC

Ganancias

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 20:40 UTC

Ganancias

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct 2025, 20:24 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:23 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:13 UTC

Ganancias

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 20:07 UTC

Charlas de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct 2025, 19:40 UTC

Charlas de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct 2025, 19:35 UTC

Charlas de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct 2025, 19:33 UTC

Ganancias

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct 2025, 19:29 UTC

Charlas de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct 2025, 18:52 UTC

Ganancias

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:41 UTC

Ganancias

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:03 UTC

Ganancias

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct 2025, 18:02 UTC

Ganancias

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct 2025, 18:00 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct 2025, 16:57 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct 2025, 16:54 UTC

Charlas de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct 2025, 16:44 UTC

Charlas de Mercado
Ganancias

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct 2025, 16:39 UTC

Charlas de Mercado
Ganancias

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct 2025, 16:33 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:23 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 16:07 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparación entre iguales

Cambio de precio

MacroGenics Inc previsión

Precio Objetivo

By TipRanks

104.92% repunte

Estimación a 12 Meses

Media 3.75 USD  104.92%

Máximo 5 USD

Mínimo 3 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MacroGenics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

3

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.47 / 1.64Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

145 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat